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OBJECTIVES: The aim of this study was to investigate the impact of chronic auto-
immune diseases, mainly rheumatoid arthritis (RA), on functional status among 
patients in Slovakia. METHODS: Patients were prospectively recruited in the 
National Institute for Rheumatic Diseases in Slovakia during 2014 and data from 
patients on disease impact on their life were collected from physicians through a 
specifically designed questionnaire. Functional status and disability assessments 
were conducted among patients with RA using the Stanford Health Assessment 
Questionnaire (HAQ). RESULTS: The sample (100 respondents) was predominantly 
female (82%) with diagnosis of RA (86%). The average age was 51 with 14-year dura-
tion of the disease average. Thirty-eight percent of patients had osteoporosis, 21% 
a cardiovascular disease and 29% patients underwent surgery due to autoimmune 
diseases – 3 times on average. The most common symptom, occurring more than 
once a week, was fatigue. Patients reported also reduced physical activity, pain 
and specifically joint pain. Manifestations of the disease were on average at a mild 
intensity. Full work disability was more common (37%) than partial work disability 
(29%) in the sample. HAQ final score ranged from 0 (no disability) to 3 (severe dis-
ability) with average HAQ score 1.35 (SD= 0.59). Majority of patients reported some 
or much difficulty in all HAQ domains and the highest disability was found for the 
domains of reach (score 1.59) and grip (1.54). HAQ score is increasing with the dis-
ease duration: average HAQ score in patients with RA lasting less than 10 years was 
significantly lower (1.17) than in patients with the disease duration of 20 years and 
more (1.61). CONCLUSIONS: Results indicate that chronic autoimmune diseases, 
mainly rheumatoid arthritis (RA), have negative impact on activities of daily living 
and the most commonly reported symptoms are fatigue and pain. Functional status 
is worsening with the duration of the disease.
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OBJECTIVES: The aim of this study was to investigate the socio-economic impact of 
chronic autoimmune diseases, mainly rheumatoid arthritis (RA) and work disabili-
ties, among patients in Slovakia. METHODS: Patients were prospectively recruited 
in the National Institute for Rheumatic Diseases in Slovakia during the year 2014 
and the data from patients on disease impact on their life were collected by con-
sulting physicians through a specifically designed questionnaire. RESULTS: The 
sample (100 respondents) was predominantly female (82%) with diagnosis of RA 
(86%). As many as 66% of the patients became permanently work disabled at the 
average age of 42 years, with full work disability being more common (37%) than 
partial work disability (29%). The occurrence of sick leave in the past 12 months 
among patients with a job was 48% with an average length of 30 days. Twenty-
three percent of respondents had to change their jobs due to the disease. Average 
personal expenses connected with the treatment in the last 3 months were 74 € , 
out of that the highest were their costs of traveling. 74% of respondents stated 
restrictive (52%) or very restrictive (22%) impact of the disease on their function-
ing, mostly in strenuous activities or sport. Three most frequently reported areas 
negatively affected by the disease were: social activities (reported by 63% respond-
ers), professional career (49%) and quality of a relationship with their partner (28%). 
Areas that have improved in comparison with the period when patients started 
their treatment were: communication with healthcare personnel and more effec-
tive therapies available. The support from patient organizations wasn’t perceived 
as significant. CONCLUSIONS: The occurrence of permanent work disability and 
sick leave was substantial in the sample. This study in patients with autoimmune 
chronic conditions - mainly RA, showed significant impact of the disease on work 
capabilities and socio-economic status.
PMS67
PrEfErEncES for nEW trEatMEntS diMiniSh in thE facE of aMbiguity
Harrison M., Bansback N.
University of British Columbia, Vancouver, BC, Canada
OBJECTIVES: Using an example of a new drug for rheumatoid arthritis which 
offers comparable effectiveness and side-effect point estimates to older drugs, we 
explore preferences for treatments labelled ‘new’. We then examine the persistence 
of preferences once ambiguity in the evidence base due to it being new is intro-
duced. METHODS: A representative Canadian population sample (n= 2837) was ran-
domized to one of three discrete choice experiment (DCE) designs, seeking choices 
between hypothetical treatments for rheumatoid arthritis with different levels of 
7 attributes: route and frequency of administration, chance of benefit, serious and 
minor side-effects, life expectancy, and uncertainty in benefit and side-effect esti-
mates. DCEs differed in whether the treatment was 1) described as new (recently 
available) or older (5 or 10 years), 2) whether a qualitative description describing 
the confidence in the evidence was included instead, or 3) both the length of time 
available and confidence in evidence was provided. We collected self-reports of 
respondent innovativeness, numeracy, and risk attitude. RESULTS: Overall, all 6 
consistent attributes influenced preferences for treatment. A preference for less 
ambiguity (more confidence) in benefit and side-effect estimates was observed, but 
no preference for a treatment labelled ‘new’ or ‘old’. Early adopters (n= 173) had a 
significant preference for ‘newer’ treatments relative to old treatments (B= 0.157, 
p= 0.045). The magnitude of preference for new treatments was comparable with 
preferences for reducing the risks of serious side-effects in this group. When the 
newness of the drug was combined with ambiguity in the evidence base, these 
preferences for ‘new’ treatments diminished. CONCLUSIONS: Preferences for inno-
vation in health care exist for some groups of people, but when presented with the 
implications of new treatments (increased ambiguity in evidence), these prefer-
ences diminished. Physicians should either avoid describing whether treatments 
are ‘new’, or qualify the implications of a ‘new’ treatment in terms of ambiguity in 
estimates of risks and benefits.
ried (77.9%), had college/graduate degrees (59.5%), and had income > $75,000 (58.7%). 
The mean HAQ scores was 0.48+0.55 with 79.2% (n= 137) having HAQ < 1, 18.5% 
(n= 37) between 1-2, and 2.3% (n= 4) > 2. 60.3% (n= 105) employed patients reported 
high knowledge and high motivation while only 7.5% (n= 13) reported low knowl-
edge and low motivation on MMS. Most employed respondents (90.4%, n= 150) did 
not miss work due to RA with mean hours lost in the last seven days reported as 
1.04+5.18 (0-40hrs). 54.4% (n= 93) reported working more than 40 hours over the past 
seven days. Employed patients reported mean score of 1.8+2.2 for work impairment 
and 2.27+ 2.35 daily activities impairment due to their RA (measured on a scale of 
0-10 where 0 was no problem and 10 was major problem). CONCLUSIONS: Within 
the employed population, RA seems to have little effect on absenteeism, work pro-
ductivity and daily activities. High motivation and knowledge (adherence) and low 
disease severity maybe significantly and independently contributing to a favorable 
patient-perceived work productivity.
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OBJECTIVES: To evaluate the relationship between medication adherence, disease 
severity and employment status in patients with rheumatoid arthritis METHODS: 
A list of 3000 patients (18-65 years) were identified from a Specialty Pharmacy data-
base. 1,041 patients with a diagnosis of rheumatoid arthritis (RA) were identified 
from the list and were invited to participate in a survey. The patients were mailed 
a cover letter, consent letter, and a demographic questionnaire. Additionally, the 
Work Productivity and Activity Impairment (WPAI) questionnaire (assess produc-
tivity losses), Health Assessment Questionnaire (HAQ; disease severity), Modified 
Morisky Scale (MMS; medication adherence) were administered. Survey responses 
were linked to clinical measures obtained from the specialty pharmacy data-
base. Descriptive and logistic regression analyses were conducted using employ-
ment status as an outcome variable and HAQ, adherence, and demographics 
as input variables. The statistical analyses were conducted using SPSS version 
22.0. RESULTS: The response rate was 30.45% (n= 317). Based on WPAI results, 
57.4% (n= 174) identified themselves as being employed. Differences in mean age 
and mean HAQ scores of employed (54.09 years; 0.48) and unemployed (64.13 years; 
0.96) were statistically significant (p< 0.001) while there was no difference in the 
disease duration (p= 0.494). 47.3% of unemployed and 21.8% employed had HAQ 
scores greater than 1. There was a statistically significant difference in employed 
vs. unemployed (p< 0.001) across disease severity based on HAQ. While there was 
no difference in the level of knowledge (p= 0.187), there was a statistically signifi-
cant difference (p< 0.001) in the level of motivation between employed (63.5% high 
motivation) and unemployed (82% high motivation) respondents. CONCLUSIONS: 
Study results showed that employed patients, while having similar disease dura-
tion and level of knowledge, reported lower motivation on the MMS adherence 
scale. Although these patients had less severe RA compared to unemployed, this 
could act as a potential barrier to chronic treatment management and needs to 
be assessed in clinical practice.
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OBJECTIVES: The ultimate goals in managing Rheumatoid Arthritis (RA) are prevent-
ing or controlling joint damage, preventing loss of function and decreasing pain. 
Assessment of disease activity is critical; therefore, guidelines recommend that 
physicians evaluate patients’ symptoms and severity. The objective of this study was 
to examine how often evaluation of disease activity and damage in patients with RA 
was documented by physicians during office visits. METHODS: We extracted 300 
records for RA patients from a unique database of physician-patient interactions 
(RealHealthData). Using Atlas.ti, we analyzed these records to evaluate how often 
the recommended assessments of disease activity was documented by physicians 
during office visits. RESULTS: Almost all physicians (92%) document the presence 
of actively inflamed joints (i.e., tender and swollen joint counts) and evidence of dis-
ease progression (i.e., loss of motion, deformity). However, only 28% and 18% docu-
ment duration of morning stiffness and fatigue respectively. And while limitation 
of function is explored, only 11% documented the degree of joint pain via a visual 
analog scale. Lastly, it was rare for physicians to document their own global assess-
ment of disease activity (5%) or the patient’s global assessment of disease activity 
(8%). CONCLUSIONS: The more we know about patients’ reported symptoms and 
outcomes, the more we can actively plan and organize research, development and 
outreach that is patient-centric and clinically meaningful. Successful treatment 
includes systematic and regular evaluation of disease activity and patient assess-
ments to help limit joint damage and functional loss. While many physicians are 
documenting the number of tender and swollen joints, loss of motion or deformity, 
a majority of physicians are not documenting patient-reported symptoms that are 
critical to disease monitoring such as morning stiffness, fatigue or overall degree of 
joint pain. Our results demonstrate there is room for improvement when it comes 
to documenting patient-reported outcomes in RA.
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targeted (44%) disease-modifying antirheumatic drug use; 84% reported current RA 
disease activity. Additional usable data were obtained including those on education, 
employment, health insurance, income, remission state, health assessment ques-
tionnaire, and patient global for the project. CONCLUSIONS: This analysis docu-
ments the feasibility of gaining rapid and relevant responses from a representative 
community RA patient population regarding their perspective on RA remission 
through our digital direct to patient portal.
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OBJECTIVES: Patient-reported outcome instruments are used in clinical trials of 
rheumatoid arthritis (RA) treatments to evaluate treatment benefits. A growing 
body of evidence suggests that joint pain, tiredness, and morning joint stiffness 
are among the most important symptoms for RA patients. A 7-item electronic 
daily diary was developed to assess these key symptom concerns of patients 
with RA for use as efficacy endpoints in clinical trials. The aim of this study was 
to evaluate the content of the diary and to ascertain whether patients with RA 
found items in the diary interpretable and relevant through concept elicitation and 
cognitive interviews. METHODS: A cross-sectional qualitative interview study was 
conducted in adults with moderate-severe RA in the US and UK. Interviews were 
conducted using a standardized interview guide to elicit information about ways 
patients with RA experience and talk about their symptoms followed by a cognitive 
interview on the dairy. Data were analyzed utilizing a qualitative analysis software 
program, Atlas.ti. RESULTS: The study sample included 28 participants (US n= 22, 
UK n= 6; 29% male; mean age 58.41 years; RA mean duration 13.92 years). Total 
HAQ-DI mean scores were 0.84 (US) and 1.50 (UK). Morning joint stiffness (n= 19), 
joint pain (n= 28), and tiredness (n= 7) were among the most commonly experi-
enced and reported symptoms; saturation of these concepts was achieved in the 
second interview. These results demonstrated that the diary includes appropriate 
content and terminology. Cognitive interviews indicated that participants found 
the diary items and response options clear, easy to understand and relevant to 
their RA experiences. No differences in qualitative results were noted between 
the two country samples. CONCLUSIONS: Results of this qualitative study sug-
gest that the 7-item electronic daily diary includes content relevant to patients 
and is suitable for assessing RA symptoms in clinical studies of patients with 
moderate to severe RA.
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OBJECTIVES: In the past decade many studies established relationship between vita-
min D deficiency and chronic musculoskeletal pain including low back pain. Present 
study aimed to examine the effect of vitamin D3 supplementation in patients with 
chronic low back pain with low level of vitamin D. METHODS: This single arm, open 
label study was conducted in a public tertiary care teaching hospital in India after 
obtaining approval from the Ethics Review Board of the hospital. Adult patients of 
either gender, aged 18 to 65 years, with a diagnosis of CLBP and low serum 25(OH)
D3 levels (< 30 ng/mL) and not responding to medications and physical therapies, 
having a pain score of at least 50 as assessed on 0 – 100 Visual Analogue scale (VAS) 
at baseline were eligible for study recruitment. Cholecalciferol (active vitamin D3) 
in a dose of 60,000 IU/week for a period of 8 weeks was given to the enrolled sub-
jects according to standard guidelines. Study endpoints include change in pain 
score and disability as measured by modified Oswestry disability questionnaire 
(MODQ). Patient information and outcome measures were collected at baseline, 2, 
3 and 6 months. RESULTS: A total of 68 chronic low back patients were included 
in the trial. Mean baseline vitamin D level is found to be 12.80+5.73 ng/ml. After 
treatment it significantly (P< 0.01) increased to 36.07+12.51. VAS (81.03+18.57) and 
MODQ (44.83+15.47) were high at baseline. Pain intensity has significantly reduced 
to 44.71+18.96 (< 0.05) and 35.74+17.75 (< 0.05) at 3 and 6 months respectively. 
Disability has significantly reduced to 30.94+12.48 (< 0.05) and 26.10+10.03 (< 0.05) 
at 3 and 6 months respectively. CONCLUSIONS: Present study shows that vitamin 
D supplementation can improve the pain and disability in patients with CLBP. Study 
results should be carefully interpreted as it is a single arm open label study and 
concomitant medication usage was not assessed.
PMS73
MiniMally iMPortant diffErEncES for PatiEnt-rEPortEd outcoMES 
MEaSurEMEnt inforMation SyStEM (ProMiS) fatiguE and Pain 
intErfErEncE ScorES
Beaumont J.L.1, Fries J.F.2, Curtis J.R.3, Cella D.4, Yun H.3
1Northwestern University, Chicago, IL, USA, 2Stanford University, Palo Alto, CA, USA, 3University 
of Alabama at Birmingham, Birmingham, AL, USA, 4Northwestern University Feinberg School of 
Medicine, Chicago, IL, USA
OBJECTIVES: Interpretation of patient-reported outcomes (PROs) requires some defi-
nition of an important or meaningful difference. This study aimed to estimate mini-
mally important differences (MIDs) for the Patient-Reported Outcomes Measurement 
Information System (PROMIS®) Fatigue and Pain Interference scale scores in rheu-
matoid arthritis (RA). METHODS: The responsiveness of several PROs was assessed 
in an observational cohort of 521 RA patients in the Arthritis, Rheumatism and Aging 
Medical Information Systems (ARAMIS) cohorts. PROMIS Fatigue and Pain Interference 
instruments were administered at baseline, 6 months, and 12 months. Self-reported 
retrospective changes in fatigue and pain over the previous 6 months were obtained at 
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OBJECTIVES: Perioperative pain management is an important aspect of recov-
ery from TKA, as severe pain can delay ambulation and hospital discharge. The 
objective of this study was to determine the impact of local infiltration analgesia 
using LB when compared to continuous femoral nerve catheter (FNC) following 
TKA. METHODS: This study enrolled consecutive patients who received a TKA 
between April 2011 and September 2014 into three study groups, excluding bilat-
eral and revision TKA. Study Group A received adductor canal infiltration with 
bupivacaine and knee infiltration with LB. Study Group B received adductor canal 
infiltration with LB and knee infiltration with LB. The control group received a con-
tinuous FNC with an OnQ pump and ropivacaine. Numeric pain rating scores (NPRS), 
distance walked, and length of stay (LOS) were the primary outcomes. RESULTS: 
A total of 237 participants were enrolled in this study, including 98 in Group A, 34 
in Group B, and 105 controls. On postoperative day (POD) 0, mean NPRS were simi-
lar between Group A (1.8±1.7), Group B (2.7±1.8), and the control group (2.3±2.4). 
Significantly (p< 0.05) more patients in Group A (58%) and Group B (44%) walked 
on POD 0 than in the control group (0%); almost all patients walked on POD1. The 
mean distance walked was also significantly greater (p< 0.05) on POD0 and on POD1 
in Group A (33±42 feet; 193±203 feet) and Group B (42±82 feet; 211±144 feet) than 
in the control group (0 feet; 46.3±73 feet). LOS was significantly (p< 0.05) shorter in 
Group B (2.2±1.7 days), than in the control group (3.2±0.7 days) and Group A (3.0±1.7 
days). CONCLUSIONS: Local infiltration analgesia using LB improved ambulation 
and LOS following TKA when compared to continuous FNC with an OnQ pump and 
ropivacaine. The one-day decrease of hospitalization suggests an estimated cost 
savings to an Illinois hospital of $2,158 per patient.
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OBJECTIVES: Fibrodysplasia Ossificans Progressiva (FOP) is a rare and disabling 
genetic condition of progressive extraskeletal bone formation. Physical function-
ing declines as FOP progresses. The objective was to develop a measure of physical 
function (PF) in adults with FOP. METHODS: We reviewed the PROMIS PF item bank 
for relevant items for FOP, and 44 PF items were identified. We then conducted 
concept elicitation (CE) interviews in 21 patients diagnosed with FOP (with varying 
levels of disease severity) who attended the International FOP Association meeting. 
The selected PF items were administered after the CE interviews. Interview data 
were analyzed to identify categories of physical functioning that were impacted by 
FOP. Based on the CE findings and PF item data, 26 items were initially selected for 
the new measure. Clinical experts in FOP reviewed the proposed set of items. Five 
additional items were incorporated into the draft measure, and cognitive interviews 
(CIs) were conducted in 10 patients, and revisions were made to the final FOP-PF 
Questionnaire (FOP-PFQ; 28 items). RESULTS: For the CE interviews, mean age was 
30 years (range 16–54) and 58% were female. For the CIs, mean age was 31 years 
(range 16–57) and 50% were female. CE interviews demonstrated substantial impacts 
of FOP on mobility, upper extremity function, and related activities. The CE findings, 
PROMIS PF item descriptive data, and discussion with clinical experts resulted in 
31 relevant items which were included in the draft FOP-PFQ. Based on the CIs, the 
majority of patients understood the instructions, questions, and response scales; 
three items were deleted due to redundancy or item removal from the original 
PROMIS item bank. CONCLUSIONS: This qualitative research supports the content 
validity of the FOP-PFQ and illustrates the application of PROMIS item banks for 
efficient new instrument development in an ultra-rare and disabling genetic disease.
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OBJECTIVES: Rheumatoid arthritis (RA) is an autoimmune disease characterized 
by significant morbidity related to systemic and joint inflammation. With the 
availability of more targeted therapeutic approaches and the potential of disease 
remission, there is increased focus on utilizing patient reported outcomes to better 
evaluate RA treatment impact. Collecting such data efficiently, i.e., with relatively 
low cost and time expenditures, can be challenging. Our objective was to imple-
ment digital direct-to-patient methodology to collect and incorporate United States 
(US) RA patient data into the Outcome Measures in Rheumatoid Arthritis Clinical 
Trials (OMERACT) project to study the patient perspective on remission. METHODS: 
Leveraging a known community (MediGuard.org) of approximately 40,000 US RA 
patients with pre-existing consent to contact for research purposes, patients were 
contacted in December 2014 to obtain 50 responses to the OMERACT survey through 
a direct-to-patient digital communications platform. Patients did not receive any 
honoraria for survey completion. RESULTS: The first survey was completed within 
seven minutes of initial digital outreach and the fiftieth within three hours. RA 
patients from 23 continental US states were represented. Of the 50 patients, 82% 
were female, mean age 54.8 years; male patients were older, mean age 61.7 years. 
RA diagnosis duration was 11.3 years average (range 1-40). Comorbidities includ-
ing other autoimmune and musculoskeletal conditions, diabetes, cardiovascular 
disease, malignancies were reported by 70%; 76% reported synthetic (72%) and/or 
